Drug class

Antiviral-HIV (Antiretroviral) Protease Inhibitors

Antiviral-HIV (antiretroviral) protease inhibitors constitute a therapeutic class of medications used primarily in combination antiretroviral therapy for the management and treatment of human immunodeficiency virus type 1 (HIV-1) infection. Read more about Antiviral-HIV (Antiretroviral) Protease Inhibitors

32 drugs in this class 20 manufacturers

Advertisement

Drugs in Antiviral-HIV (Antiretroviral) Protease Inhibitors

Showing 1–9 of 32 drugs

APTIVUS (tipranavir)

ANTIVIRAL-HIV (ANTIRETROVIRAL) PROTEASE INHIBITORS · HIV INFECTION
Boehringer Ingelheim

PREZISTA (darunavir)

ANTIVIRAL-HIV (ANTIRETROVIRAL) PROTEASE INHIBITORS · HIV INFECTION
JANSSEN PRODUCT

PREZISTA (darunavir)

ANTIVIRAL-HIV (ANTIRETROVIRAL) PROTEASE INHIBITORS · HIV INFECTION
JANSSEN PRODUCT
Filter & compare in the drug finder → Opens the drug finder with Antiviral-HIV (Antiretroviral) Protease Inhibitors preselected. Add indication or manufacturer filters there.

About Antiviral-HIV (Antiretroviral) Protease Inhibitors.

Antiviral-HIV (antiretroviral) protease inhibitors constitute a therapeutic class of medications used primarily in combination antiretroviral therapy for the management and treatment of human immunodeficiency virus type 1 (HIV-1) infection.

These agents function by binding selectively to the active site of the viral HIV protease enzyme, which prevents the essential cleavage of nascent Gag and Gag-Pol precursor polyproteins.

By disrupting this critical maturation step during viral replication, the drugs prevent the formation of mature, infectious virions, thereby lowering viral load and impeding progression to acquired immunodeficiency syndrome (AIDS).